ENTX (Entera Bio) Ending Cash Position: $12.02 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ENTX Entera Bio Ltd ENTX
32 GF Score
Price $2.96
! 4 Warning Signs
View Full Analysis

What is Entera Bio Ending Cash Position?

Entera Bio ENTX -0.02% 32 Ending Cash Position is $12.02 Mil as of Mar. 2026. GuruFocus rates ENTX with a GF Score™ of 32/100. The stock has 4 warning signs investors should review.

Entera Bio's Ending Cash Position for the quarter that ended in Mar. 2026 was $12.02 Mil.

Entera Bio's quarterly Ending Cash Position declined from Sep. 2025 ($16.69 Mil) to Dec. 2025 ($14.97 Mil) and declined from Dec. 2025 ($14.97 Mil) to Mar. 2026 ($12.02 Mil).

Entera Bio's annual Ending Cash Position declined from Dec. 2023 ($11.09 Mil) to Dec. 2024 ($8.74 Mil) but then increased from Dec. 2024 ($8.74 Mil) to Dec. 2025 ($14.97 Mil).

Entera Bio Ending Cash Position Related Terms

Entera Bio Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Entera Bio's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entera Bio Ending Cash Position Chart

Entera Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.96 12.38 11.09 8.74 14.97

Entera Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.67 18.95 16.69 14.97 12.02
ENTX
32GF Score
Entera Bio Ltd ENTX
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Entera Bio Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Entera Bio's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=8.776+6.197
=14.97

Entera Bio's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=14.973+-2.956
=12.02

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $12.02 Mil mean?
Entera Bio (ENTX) has a Ending Cash Position of $12.02 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Entera Bio and its competitors.
Is Entera Bio's Ending Cash Position too high?
Entera Bio's current Ending Cash Position is $12.02 Mil. Overall, Entera Bio has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Entera Bio's Ending Cash Position compare to ICCC and BDTX?
Entera Bio's Ending Cash Position of $12.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Entera Bio and its competitors. Entera Bio's current Ending Cash Position is $12.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entera Bio stock overvalued right now?
Entera Bio (ENTX) has a current Ending Cash Position of $12.02 Mil. The current Ending Cash Position is $12.02 Mil. Entera Bio's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Entera Bio (ENTX), the current Ending Cash Position is $12.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entera Bio Business Description

Other Exchanges 5DT:Germany
Address Kiryat Hadassah, Minrav Building - Fifth Floor, Hadassah Bio Park, Jerusalem, ISR, 9112002
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
32GF Score

Get the complete analysis for ENTX

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.96
Price